CRSF 07th Masterclass: 5-Year OS with Tecentriq in ES-SCLC | Panel Discussion with Experts

Frontline Therapy Approaches for Small Cell Lung CancerПодробнее

Breaking Boundaries: 5-Year Survival in ES SCLC | CRSF 7th Annual Lung Cancer ReviewПодробнее

Treatment Landscape of Extensive Stage SCLC: Overview and Lurbinectedin - 2024 Lung Cancer OncTalkПодробнее

Understanding and Implementing the New CoC Lung Cancer Standards (April 28, 2022)Подробнее

BEAT-SC: Phase III trial of bevacizumab or placebo with atezolizumab & chemo in extensive-stage SCLCПодробнее

Alexander Spira, MD, PhD, FACP, on the recent approval of atezolizumab in SCLCПодробнее

Interview with CSHL Professor Rob MartienssenПодробнее

TCTMD Webcast Cobra Reduce Study InterviewsПодробнее

Results of CeLEBrATE: carboplatin, etoposide, bevacizumab + atezolizumab ES-SCLCПодробнее

tecentriqПодробнее

Concurrent immunotherapy in SCLCПодробнее

Networked | Eric Tiegel & Scott Sandberg | S5 E7Подробнее

Approaching Non-Driver Stage IV NSCLCПодробнее

Four chemo cycles given with durvalumab ± tremelimumab optimise response in patients with mNSCLCПодробнее